|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, Vol. 91 No. 10 (May 15), 1998:
pp. 3746-3755
By
From the Department of Cancer Biology, The Lerner Research Institute
of the Cleveland Clinic Foundation, Cleveland, OH.
SHP-1 protein tyrosine phosphatase is a critical negative regulator
of mitogenic signaling, as demonstrated by the heightened growth
responses to hematopoietic growth factors in hematopoietic cells of
motheaten mice, which lack functional SHP-1 expression due to mutations
in the SHP-1 gene. The mitogenic signaling molecules dephosphorylated
by SHP-1 have not been fully identified. We detected two proteins
(p32/p30) that are hyperphosphorylated in a DA3/erythropoietin receptor
(EpoR) cell line that expresses a mutant containing the SHP-1
C-terminus that suppresses the function of the endogenous phosphatase
and induces hyperproliferative responses to interleukin-3 (IL-3) and
Epo. Hyperphosphorylated p32/p30 are also detected in motheaten
hematopoietic cells, demonstrating an association of p32/p30
hyperphosphorylation with SHP-1-deficiency and growth factor-hyperresponsiveness. The hyperphosphorylated p32/30 associate with SHP-1 via its C-terminus, because they coimmunoprecipitate with
the phosphatase and the C-terminal mutant and they bind in vitro to a
synthetic peptide of the mutant but not the GST fusion proteins of
SHP-1 SH2 domains. Induction of p32/p30 phosphorylation by IL-3 or Epo
occurs mainly at 2 to 18 hours poststimulation in the DA3/EpoR cell
line, indicating p32/p30 as novel signaling molecules during cell cycle
progression. These data demonstrate a function for the SHP-1 C-terminus
in recruiting potential substrates p32/p30 and suggest that SHP-1 may
regulates mitogenic signaling by dephosphorylating p32/p30.
HEMATOPOIETIC growth factors, such as
interleukin-3 (IL-3) and erythropoietin (Epo), play critical roles in
hematopoiesis. Signal transduction for both IL-3 and Epo depends on the
induction of tyrosine phosphorylation to activate the Ras and the Jak2
signaling pathways.1 The receptors for IL-3
(IL-3R) and Epo (EpoR) have no intrinsic kinase activity. Ligand
binding activates the receptor-coupled Jak2 protein tyrosine
kinase.2,3 As shown by mutational analysis, the IL-3R and
EpoR have distinct functional domains mediating the two signaling
pathways.4,5 The membrane proximal part of the receptor
cytoplasmic region is required for the activation of the Jak2 tyrosine
kinase, STAT5 phosphorylation, and c-myc expression. The carboxyl
terminal region of the receptor is responsible for activating the Ras
pathway, leading to MAPK phosphorylation and c-fos expression. Whereas
the activation of the Ras pathway is not required for mitogenic
signaling, it is important for cell viability by preventing
apoptosis6 and may also promote cell proliferation.7 On the other hand, activation of the Jak2
pathway and the induction of c-myc expression correlate with signaling of cell proliferation.5 However, the molecule(s) that
mediates mitogenic signals downstream from the Jak/Ras pathways to
apparatus controlling cell cycle progression has not been unequivocally identified. Although STAT5 activation enhances the cell proliferative response,8 it is not required for mitogenic
signaling.5 Importantly, the signal transduction for IL-3
and Epo is also regulated by protein tyrosine phosphatases (PTPases),
because the tyrosine phosphorylation induced by either of the growth
factors is transient and returns to basal levels shortly after ligand stimulation.9,10
SHP-1 (previously called PTP1C/HCP/SHPTP1/SHP) is a cytoplasmic protein
tyrosine phosphatase that contains two SH2 domains and is expressed
predominantly in hematopoietic cells.11-15 Previous studies
from our laboratory and others demonstrate that SHP-1 is a critical
negative regulator of the mitogenic signaling of IL-3 and Epo.
Hematopoietic cells from the motheaten mice, which lack functional
SHP-1 due to mutations in the SHP-1 gene,16,17 are
hyperproliferative in response to Epo,18 macrophage
colony-stimulating factor (M-CSF),19 and
granulocyte-macrophage colony-stimulating factor
(GM-CSF).20 This hyperproliferation is likely one of the
factors responsible for the elevated myelopoiesis of erythroid, monocytic, and granulocytic lineages in motheaten mice and for the
early death of the mice from massive accumulation of myeloid cells in
vital organs.21 The observation that overexpression of
SHP-1 suppresses IL-3-induced cell proliferation in a murine IL-3-dependent cell line provides additional support for a negative role for the phosphatase in mitogenic signaling.22
Furthermore, we and others have shown that SHP-1 associates with the
receptors for hematopoietic growth factors, such as IL-3,22
Epo,23,24 and stem cell factor,25 through its
SH2n domain that bind to phosphotyrosine sites in the cytoplasmic
regions of the receptors. In addition, SHP-1 also associates with and
regulates signals from membrane molecules of other receptor complexes,
such as Fc SHP-1 regulates mitogenic signaling by dephosphorylating key substrates
essential for cell proliferation. The Jak family kinases have been
implicated as SHP-1 substrates in recent studies. It was
shown23 that an EpoR mutant, which has two of the tyrosines in the cytoplasmic domain substituted with phenylalanines and was not
recognized by SHP-1 SH2 domains, caused marked and prolonged Jak2
hyperphosphorylation in response to Epo stimulation. This suggests that inhibition of SHP-1 binding to the receptor prevented it
from dephosphorylating Jak2 and may have enhanced mitogenic signaling.
However, the hypothesis is complicated by the observation that
comparable Jak2 phosphorylation was detected from engagement of the
wild-type EpoR or an EpoR null mutant with all of the tyrosines in the
receptor cytoplasmic domain substituted by phenylalanines.8 Moreover, it was shown recently that SHP-1 directly binds to and dephosphorylates Jak family kinase.33 Importantly, we found that GM-CSF stimulation of motheaten macrophages, which are
hyperproliferative in response to the growth factor, induces only a
rather modest and transient Jak2 hyperphosphorylation, whereas the
cells contain several yet unidentified proteins that are markedly
hyperphosphorylated.24 This suggests that SHP-1 may play a
limited role in Jak2 dephosphorylation and that SHP-1 may regulate
mitogenic signaling by dephosphorylating additional substrates.
To identify key substrates of SHP-1 and elucidate mitogenic signaling
pathways, we sought to suppress the endogenous SHP-1 activity in a
murine myeloid cell line (DA3EpoR) that depends on IL-3 or Epo for
proliferation by introducing dominant negative SHP-1 mutants into the
cells and to characterize hyperphosphorylated proteins induced by the
mutant. Previous studies showed that deletion of the C-terminus of
SHP-1 increased the SHP-1 PTPase catalytic activity,34-36
suggesting that the C-terminus is inhibitory to the phosphatase. We
examined Epo/IL-3 growth responses and phosphotyrosine proteins of
DA3EpoR cells expressing an SHP-1 mutant containing the C-terminus of
phosphatase. Two SHP-1-associated proteins, p32/p30, were detected
whose hyperphosphorylation correlates with defective SHP-1 activity and
cell hyperproliferation. Our data indicate that p32/p30 are novel SHP-1
substrates that function understream of Jak/Ras pathways and during
cell cycle progression in mitogenic signaling of Epo/IL-3.
Cells and cell culture.
PA317 cells37 were maintained in Dulbecco's modified
Eagle's medium (DMEM) with 10% fetal calf serum (FCS). The growth
factor-dependent murine myeloid cell line DA3EpoR10 and
DA3EpoR-H/Y343F5 were maintained in RPMI 1640 medium
supplemented with 10% FCS and 10% WEHI-3 conditioned medium (WCM) as
a source of IL-3 (~30 U/mL). Spleen cells and bone marrow-derived
macrophages from normal and viable motheaten mice were prepared as
previously described.20,33,38
SHP-1-C mutant, transfection, and retroviral infection of DA3EpoR
cells.
The SHP-1 C-terminus cDNA was generated by polymerase chain
reaction39 from a murine SHP-1 cDNA clone15
with synthetic oligonucleotide primers
(5 RNA isolation and Northern hybridization.
Total cellular RNA was isolated from cells following the procedures
previously described.20,33,38,39,43 The RNA samples (~20
µg/well) were separated in 1.2% agarose formaldehyde gel by
electrophoresis. The RNA samples were then blotted onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH), probed with a
32P-labeled random-primed cDNA fragment encoding the
SHP-1-C mutant, and detected by autoradiography.
Antibodies, immunoprecipitation, binding assays, and Western
blotting.
Antibodies against SHP-1,15 Jak2,3
EpoR,24 and IL-3R22 have been described
previously. The antiserum against SHP-1 C-terminus was developed in
rabbits with a synthetic peptide (KVKKQRSADKEKNKGSLKRK), whereas the
anti-SHP-1-M antibody recognizes a peptide sequence from the middle
section of the phosphatase (QKQEVKNLHQRLEGQRPENK). The hybridoma cell
line of anti-KT3 monoclonal antibody was a gift from Dr G. Walter (San
Diego, CA) and the antibody was purified from mouse ascites following
established procedures.40 Antibodies against
phosphotyrosine (anti-ptyr; UBI, Lake Placid, NY), STAT5 (Santa Cruz,
Santa Cruz, CA), phospho-MAPK (Promega, Madison, WI), c-myc (UBI), and c-fos (Santa Cruz) were purchased
from commercial sources.
Phosphatase assays.
The preparation of GST fusion protein of SHP-1 has been described
previously.28 The phosphatase (PTPase) activity of the GST-SHP-1 fusion protein was determined using pNPP (Sigma) as a
substrate. The PTPase assay was performed in the absence or presence of
synthetic peptide SHP-1-C (20 to 40 µmol/L) at 22°C for 30 minutes in 50 mL of reaction mixture (100 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L dithiothreitol, 10 mmol/L pNPP, and 20 nmol/L GST-SHP-1). The reaction was terminated by
adding 950 mL of 1 N NaOH. The reaction product p-nitrophenolate was
quantified by measuring absorbance at 405 nm.
An SHP-1 mutant (SHP-1-C) containing the C-terminus of the phosphatase
induces heightened growth response to IL-3 and Epo in DA3EpoR cells.
An SHP-1 mutant (SHP-1-C) containing the C-terminal 45 amino acids of
the phosphatase was tagged with the KT3 epitope
(Fig 1A) and introduced, by retroviral
infection in pBabe vector carrying the puromycin-resistant gene, into
the murine myeloid cell line DA3EpoR that depends on IL-3 or Epo for
proliferation. Puromycin-resistant populations of DA3EpoR cells
infected with the mutant (D/C) or the control vector (D/V) were further
characterized. SHP-1-C transcript was detected by Northern
hybridization in D/C but not D/V cells (Fig 1B, lanes 1 and 2). The
SHP-1-C transcript in D/C cells was expressed at about twofold to
threefold higher than that of the endogenous SHP-1. SHP-1-C protein
expression was detected in D/C (Fig 1C, upper panel, lanes 2 and 3) but
not in D/V cells (Fig 1C, lower panel, lanes 2 and 3), as expected.
SHP-1-C induced hyperphosphorylation of p32/p30 but had no marked
effect on the activation of Jak2 and Ras pathways.
Because suppression of endogenous SHP-1 by the SHP-1-C mutant should
cause hyperphosphorylation in the substrates of SHP-1, we examined
Epo-induced protein tyrosine phosphorylation in D/V and D/C cells. In
comparison with D/V cells, D/C cells contained several distinct
proteins that were hyperphosphorylated. Among these, two proteins of
approximately 32 and 30 kD (p32/p30) were prominent
(Fig 2A), with p32 hyperphosphorylation
more pronounced than p30. The phosphorylation of p32/p30 in D/V cells,
as in the parental DA3EpoR cells (data not shown), was modestly and
transiently induced by Epo at 10 minutes (Fig 2A, lane 3) and then
again at 120 minutes after stimulation (Fig 2A, lane 6). p32/p30
phosphorylation in D/C cells was generally onefold to fourfold higher
than that in D/V cells with or without Epo stimulation (Fig 2A, lanes 7 through 11; see also Figs 4 and 5) and were also further induced at 120 minutes after stimulation (Fig 2A, lane 12). In addition, increased
phosphorylation was also detected in yet unidentified proteins of
approximately 150, 104, 56, and 53 kD (Fig 2A, lanes 7 through 12). In
contrast, Epo-induced phosphorylation of EpoR (Fig 2A), Jak2 (Fig 2D),
and Stat5 (data not shown) were comparable in D/V and D/C cells, with a
minor increase of Jak2 phosphorylation in growth factor-deprived D/C
cells (compare Fig 3C and D, lanes 1 and
7). Consistent with the lack of effect of SHP-1-C mutant on Jak2/Stat5
phosphorylation, Epo induced similar expression levels of c-myc (Fig
2C) and c-fos (data not shown) in both cell populations. Similar
results were obtained when the cells were stimulated with IL-3 (data
not shown).
Reduced induction of p32/p30 phosphorylation from the EpoR mutant
H/Y343F that was defective in Ras but not Jak2 activation.
The late induction of p32/p30 phosphorylation at 2 hours after Epo
stimulation indicates that it is a signaling event downstream of the
Jak/Ras signaling pathways that are activated transiently (1 to 60 minutes) after Epo/IL-3 stimulation. Using an IL-3-responsive cell
line (DA3EpoR-H/Y343F) that expresses an EpoR mutant competent in
activating the Jak2 but not the Ras pathway,5 we examined the relative roles of the Jak2 and Ras activations in the induction of
p32/p30 phosphorylation.
p32/p30 phosphoproteins associate with SHP-1-C and SHP-1 in D/C
cells.
To detect phosphotyrosine proteins that interact with SHP-1-C or the
endogenous SHP-1, we immunoprecipitated the mutant and SHP-1 from D/V
and D/C cells using antibodies specific for the mutant (anti-KT3) or
SHP-1 (anti-SHP-1-M; Fig 1A). p32 and p30 phosphoproteins were detected
in the SHP-1-C and SHP-1 immunocomplexes from the D/C
(Fig 4A, lanes 4 and 6), demonstrating that
p32/p30 associated with SHP-1-C and SHP-1 in vivo in D/C cells. This
association was specific, because the hyperphosphorylated p56 and p53
in D/C cells were not detected in the immunocomplexes under comparable conditions. The result also showed that SHP-1 and SHP-1-C associated with the phosphoproteins independently because SHP-1 was not detected in the SHP-1-C immunocomplexes (Fig 4A, lane 4). Because the GST fusion
protein of SHP-1 SH2 domains bound to phosphorylated EpoR but not
p32/p30 in vitro (Fig 4B, lane 8), it indicated that the association of
p32/p30 with SHP-1 was mediated via the C-terminus of the phosphatase
and that the SHP-1-C mutant competes against SHP-1 for p32/p30
association. In addition, phosphotyrosine proteins of approximately 48 and 26 kD (p48 and p26) were also detected in the immunocomplexes (Fig
4A, lanes 4 and 6) with weaker and less consistent signals, suggesting
that their association with SHP-1 and SHP-1-C was unstable or indirect.
Interestingly, phosphorylated p32/p30 were not detected in SHP-1
immunocomplexes from D/V cells (Fig 4A, lane 3). Whether
unphosphorylated forms of p32/p30 associate with SHP-1 in D/V cells
remains to be determined.
Synthetic peptide of SHP-1-C bind to p32/p30 in D/V and D/C cells and
is inactive against SHP-1 PTPase in vitro.
To further define the interactions of SHP-1 with p32/p30, we examined
the binding of a synthetic peptide of the SHP-1-C to the
phosphoproteins in vitro. The peptide bound to p32/p30 in D/V and D/C
cells (Fig 5A, lanes 3 and 4 of the upper
panel). This association of p32/p30 with the SHP-1-C peptide did not
require the SHP-1 phosphatase (Fig 5A, lanes 3 and 4 of the lower
panel), consistent with the independent association of p32/p30 with
SHP-1-C and SHP-1 in vivo (Fig 4A). Interestingly, phosphorylated
p32/p30 in association with the peptide from D/V were twofold to
threefold higher than those from D/C cells. This indicated that
pre-existing complexes of SHP-1-C mutant and p32/p30 in D/C cells (Fig
4A, lane 6) reduced the amount of p32/p30 available for binding to the
SHP-1-C peptide. It also demonstrated that p32/p30 in D/V cells had
SHP-1-C binding activity. Thus, the failure of p32/p30 to
coimmunoprecipitate with SHP-1 in D/V cells (Fig 4A, lane 3) may result
from failure of the C-terminus of SHP-1 to interact with p32/p30.
Induction of p32/p30 phosphorylation at 2 to 18 hours after Epo
stimulation.
The induction of p32/p30 phosphorylation at 2 hours after stimulation
(Fig 2A) prompted us to examine p32/p30 phosphorylation in D/V and D/C
cells at later stages after stimulation. Consistent with data shown in
Fig 2, p32/p30 phosphorylation was induced about twofold to threefold
at 2 hours after Epo stimulation in both cell populations
(Fig 6A, lanes 2 and 8). The
phosphorylation of p32/p30 was further induced twofold to fourfold from
6 to 18 hours after stimulation, with those in the D/C cells threefold to sixfold higher than those in the D/V cells at each of the time points (lanes 3 through 6 and 9 through 12). Increased phosphorylation in proteins of 48 and 26 kD (p48 and p26) in D/C cells was also detected (Fig 6A). Phosphorylated p32/p30 coimmunoprecipitated with
SHP-1 (Fig 6B, lanes 1 through 6) and the SHP-1-C mutant (data not
shown) from D/C but not D/V cells (Fig 6B, lanes 1 through 6), despite
their existence in D/V cell lysates (Fig 6A, lanes 1 through 6).
Similar results were derived from D/V and D/C cells stimulated with
IL-3 (data not shown).
Hyperphosphorylated p32/p30 are major novel proteins in SHP-1-C
immunocomplexes.
To determine the relative amounts of p32/p30 in SHP-1-C
immunocomplexes, anti-KT3 immunocomplexes from D/V or D/C cells were separated in an SDS-PAGE gel in duplicates and analyzed by either direct Coomassie Blue staining or by Western blotting with an anti-ptyr
antibody. As expected, hyperphosphorylated p32/p30 were detected by
Western blotting in the immunocomplex from D/C cells (Fig 7, lane 3) but not from D/V cells (Fig
7, lane 4). Two proteins that comigrate with the hyperphosphorylated
p32/p30 were detected uniquely in the immunocomplex from D/C cells (Fig
7, lane 1), indicating that these two proteins were likely to be the
hyperphosphorylated p32/p30 and were among the major proteins in
association with SHP-1-C. In addition, tyrosine-phosphorylated p48 and
p26 were also detected in complexes with p32/p30 (Fig 7, lane 3). Using a similar approach, we found that proteins of 32 and 30 kD were also
among the major cellular proteins associated with the SHP-1-C peptide
in binding assays (data not shown). However, it was not clear whether
SHP-1-C interacted with p32/p30 directly or indirectly, because
additional cellular proteins were also presented in the immunoprecipitation and peptide binding complexes.
Hyperphosphorylation and SHP-1 association of p32/p30 in motheaten
hematopoietic cells.
The hyperphosphorylation of p32/p30 in D/C cells indicated that p32/p30
are potential novel SHP-1 substrates. In support of this, we found that
hyperphosphorylated proteins that comigrated with the p32/p30 of D/C
cells in SDS-PAGE were also detectable in the spleen cells
(Fig 8A) and bone marrow macrophages (Fig 8C) of viable motheaten mouse, which express two forms of catalytically inactive SHP-1 proteins.16 Reminiscent of the results from
D/V and D/C cells, we also found that the hyperphosphorylated p32/30 coimmunoprecipitated with the inactive SHP-1 proteins from viable motheaten spleen cells (Fig 8B, lane 2) and macrophages (data not
shown), whereas the SHP-1-C peptide bound to p32/p30 from normal as
well as motheaten cells. In consistence with previous studies, we
detected a phosphoprotein of 120 to 130 kD20 and several
yet-unidentified proteins in the SHP-1 immunocomplexes from the
motheaten cells (Fig 8B, lane 2). The larger number of phosphoproteins
in association with the catalytically inactive SHP-1 in motheaten cells
than with the SHP-1 in D/C cells is consistent with the notion that
SHP-1-C only block the C-terminal function of the phosphatase. As in
D/V cells, GM-CSF induced an early and modest p32/p30 phosphorylation
in normal mouse macrophages (Fig 8C, lane 2). But we failed to detect
marked induction of p32/p30 phosphorylation in normal or motheaten
macrophages after CSF-1 or GM-CSF stimulation at later stages (data not
shown). It is known that the primary macrophages express lower levels
of hematopoietic receptors and proliferate at a much slower rate than
the established DA3 cell lines. Whether the lack of marked late
induction of p32/p30 in these primary cells was due to these
differences or whether it was a cell lineage-specific character has not
been determined.
DA3EpoR cells expressing the SHP-1-C mutant (D/C cells) show heightened
cell proliferation in response to Epo/IL-3 and contain hyperphosphorylated proteins similar to those detected in the motheaten
cells that lack functional SHP-1. This indicates that the mutant blocks
the function of the endogenous SHP-1 in D/C cells and causes
hyperphosphorylation in SHP-1 substrates involved in mitogenic
signaling of Epo/IL-3. Identification of these substrates is essential
in understanding SHP-1 function and in elucidating mitogenic signaling
pathways of the hematopoietic growth factors.
Submitted August 4, 1997;
accepted January 12, 1998.
The authors thank Dr G. Walter for the anti-KT3 hybridoma cell line, Dr
J. Ihle for the DA3EpoR-H/Y343F cell line, and Drs Christine Campbell
and Robert Silverman for critical reading of the manuscript.
1.
Ihle JN:
Cytokine receptor signalling.
Nature
377:591,
1995[Medline]
[Order article via Infotrieve]
2.
Silvennoinen O,
Witthuhn BA,
Quelle FW,
Cleveland JL,
Yi T,
Ihle JN:
Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction.
Proc Natl Acad Sci USA
90:8429,
1993
3.
Witthuhn BA,
Quelle FW,
Silvennoinen O,
Yi T,
Tang B,
Miura O,
Ihle JN:
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
Cell
74:227,
1993[Medline]
[Order article via Infotrieve]
4.
Mui AL,
Wakao H,
O'Farrell AM,
Harada N,
Miyajima A:
Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs.
EMBO J
14:1166,
1995[Medline]
[Order article via Infotrieve]
5.
Quelle FW,
Wang D,
Nosaka T,
Thierfelder WE,
Stravopodis D,
Weinstein Y,
Yi T,
Ihle JN:
Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response.
Mol Cell Biol
16:1622,
1996[Abstract]
6.
Kinoshita T,
Yokota T,
Arai K,
Miyajima A:
Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors.
EMBO J
14:266,
1995[Medline]
[Order article via Infotrieve]
7.
Perkins GR,
Marshall CJ,
Collins MK:
The role of MAP kinase kinase in interleukin-3 stimulation of proliferation.
Blood
87:3669,
1996
8.
Damen JE,
Wakao H,
Miyajima A,
Krosl J,
Humphries RK,
Cutler RL,
Krystal G:
Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation.
EMBO J
14:5557,
1995[Medline]
[Order article via Infotrieve]
9.
Isfort R,
Huhn RD,
Frackelton A Jr,
Ihle JN:
Stimulation of factor-dependent myeloid cell lines with interleukin 3 induces tyrosine phosphorylation of several cellular substrates.
J Biol Chem
263:19203,
1988
10.
Miura O,
D'Andrea A,
Kabat D,
Ihle JN:
Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis.
Mol Cell Biol
11:4895,
1991
11.
Adachi M,
Fishcher EH,
Ihle J,
Imai K,
Jirik F,
Neel B,
Pawson T,
Shen S,
Thomas M,
Ullrich A,
Zhao Z:
Mammaliam SH2-containing protein tyrosine phosphatases.
Cell
85:15,
1996[Medline]
[Order article via Infotrieve]
12.
Matthews RJ,
Bowne DB,
Flores E,
Thomas ML:
Characterization of hematopoietic intracellular protein tyrosine phosphatases: Description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences.
Mol Cell Biol
12:2396,
1992
13.
Plutzky J,
Neel BG,
Rosenberg RD:
Isolation of a src homology 2-containing tyrosine phosphatase.
Proc Natl Acad Sci USA
89:1123,
1992
14. (erratum 353:868, 1991)
Shen SH,
Bastien L,
Posner BI,
Chretien P:
A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases.
Nature
352:736,
1991[Medline]
[Order article via Infotrieve]
15.
Yi TL,
Cleveland JL,
Ihle JN:
Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13.
Mol Cell Biol
12:836,
1992
16.
Shultz LD,
Schweitzer PA,
Rajan TV,
Yi T,
Ihle JN,
Matthews RJ,
Thomas ML,
Beier DR:
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.
Cell
73:1445,
1993[Medline]
[Order article via Infotrieve]
17.
Tsui HW,
Siminovitch KA,
de Souza L,
Tsui FW:
Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene.
Nat Genet
4:124,
1993[Medline]
[Order article via Infotrieve]
18.
Van Zant G,
Shultz LD:
Hematopoietic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev).
Exp Hematol
17:81,
1989[Medline]
[Order article via Infotrieve]
19.
Chen H,
Chang S,
Trub T,
Neel BG:
Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1.
Mol Cell Biol
16:3685,
1996[Abstract]
20.
Jiao H,
Yang W,
Berrada K,
Tibrizi M,
Shultz L,
Yi T:
Macrophages from motheaten and viable motheaten mutant mice show increased proliferative response to GM-CSF: Detection of potential HCP substrates in GM-CSF signal transduction.
Exp Hematol
25:592,
1997[Medline]
[Order article via Infotrieve] |
Abstract
Introduction
Abstract
RIIB1,
/
,
-GGAATTCAGGATGAAGGCCTCGCGTACTTCC and 5
) or with (+) Epo for 5 minutes were used in
anti-EpoR immunoprecipitation (lanes 1 through 4) or in in vitro
binding assays with a GST fusion protein of SHP-1 SH2 domains containing amino acids 1-198 of the murine SHP-1 (lanes 5 through 8).
Phosphoproteins were analyzed by SDS-PAGE/Western blotting with an
anti-ptyr antibody. The higher level of EpoR phosphotyrosine signaling
from D/C cells (lane 8) was not reproducible and may have been caused
by variations in the amount of fusion proteins. The positions of
phosphoproteins and protein size markers are indicated.
074-GIA ) to T.Y.